Active Ingredient

• Levofloxacin (as Hemihydrate) 500 mg & 750 mg

Dosage Form:

Film-Coated Tablet

Dosage

• Standard Dosing Regimen (500 mg): 1 tablet (500 mg) once daily for 7 to 14 days, based on infection severity and clinical guidelines.
• High-Dose Short-Course Regimen (750 mg): 1 tablet (750 mg) once daily for 5 days for targeted acute respiratory and complicated skin/urinary infections.
• Administration Notes: Swallow tablets whole with water. Can be taken with or without food. Maintain adequate fluid intake during treatment.

Therapeutic Class

• Broad-Spectrum Fluoroquinolone Antibacterial Agent

Indications

1. Respiratory Tract Infections: Community-Acquired Pneumonia (CAP), Hospital-Acquired Pneumonia, Acute Bacterial Sinusitis, and Acute Exacerbation of Chronic Bronchitis.
2. Urinary Tract Infections (UTIs): Complicated Urinary Tract Infections (cUTI) and Acute Pyelonephritis.
3. Skin & Soft Tissue Infections: Complicated and Uncomplicated Skin and Skin Structure Infections (SSTIs).
4. Other Systemic Infections: Chronic Bacterial Prostatitis and Post-Exposure Inhalational Anthrax.

Key Benefits

• Broad-Spectrum Bactericidal Coverage: Delivers rapid bactericidal action against a comprehensive range of Gram-positive, Gram-negative, and atypical pathogens (including Streptococcus pneumoniae, Haemophilus influenzae, Pseudomonas aeruginosa, Mycoplasma, and Legionella).
• High-Dose, Short-Course Protocol (750 mg / 5 Days): The 750 mg dosage enables an accelerated 5-day treatment course, driving rapid bacterial eradication, faster patient recovery, and reduced risk of antibiotic resistance.
• Exceptional Tissue & Respiratory Penetration: Achieves high clinical concentrations directly at target infection sites, including pulmonary tissue, bronchial mucosa, epithelial lining fluid (ELF), and urinary tract mucosa.
• Convenient Once-Daily Dosing: Features an extended half-life that allows for once-daily administration, maximizing patient convenience and compliance over multi-dose regimens.
• High Oral Bioavailability (~99%): Exhibits near-complete oral absorption equivalent to intravenous (IV) administration, enabling smooth IV-to-oral step-down therapy.